Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer
Abstract Background Hepatocyte growth factor (HGF) is a peptide-containing multifunctional cytokine, which is overexpressed and/or activated in multiple malignancies and is reported to be associated with tumor development and inferior survival. At present, the role of HGF in small cell lung cancer (SCLC) has not been fully explored yet. Materials and methods The expression of HGF and its value in predicting survival in SCLC were explored from GEO database and in pan-cancer analysis. Furthermore, we detected the expression of HGF using tumor tissue and paired plasma samples from a validation cohort of 71 SCLC patients at our institute. Correlation between tumor and plasma HGF expression and the prognostic values were analyzed. Results GEO database analysis revealed that tumor tissue had lower HGF expression than paired normal tissue in SCLC. At our institute, immunohistochemical staining showed negative expression of HGF in tumor tissue of SCLC at our institute (47/47, 100%). The average baseline plasma HGF was 1.28 (range,0.42–4.35) ng/ml. However, plasma HGF was higher in SCLC patients with patients with N3, M1, liver metastasis (LM) and bone metastasis (BM) disease compared with those N0 − 2 (1.25 vs. 1.75 ng/mL, P = 0.000), M0 (1.26 vs. 1.63 ng/mL, P = 0.003), non-LM (1.32 vs. 2.06 ng/mL, P = 0.009), and non-BM (1.35 vs. 1.77 ng/mL, P = 0.047), respectively. Multivariate analysis revealed plasma HGF was an independent predictor for LM and prognostic factor of OS. Conclusion Our results revealed that plasma HGF rather than tumor HGF exhibited a potential role in predicting metastasis and survival in SCLC. Plasma HGF might be used as a non-invasive detecting and monitoring tool for SCLC..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
BMC Cancer - 23(2023), 1, Seite 10 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cong Zhao [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
Hepatocyte growth factor |
---|
doi: |
10.1186/s12885-023-10995-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ091924588 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ091924588 | ||
003 | DE-627 | ||
005 | 20240414143723.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240412s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12885-023-10995-z |2 doi | |
035 | |a (DE-627)DOAJ091924588 | ||
035 | |a (DE-599)DOAJf270c847156348d9b5bf9ed95e9493e3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC254-282 | |
100 | 0 | |a Cong Zhao |e verfasserin |4 aut | |
245 | 1 | 0 | |a Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Background Hepatocyte growth factor (HGF) is a peptide-containing multifunctional cytokine, which is overexpressed and/or activated in multiple malignancies and is reported to be associated with tumor development and inferior survival. At present, the role of HGF in small cell lung cancer (SCLC) has not been fully explored yet. Materials and methods The expression of HGF and its value in predicting survival in SCLC were explored from GEO database and in pan-cancer analysis. Furthermore, we detected the expression of HGF using tumor tissue and paired plasma samples from a validation cohort of 71 SCLC patients at our institute. Correlation between tumor and plasma HGF expression and the prognostic values were analyzed. Results GEO database analysis revealed that tumor tissue had lower HGF expression than paired normal tissue in SCLC. At our institute, immunohistochemical staining showed negative expression of HGF in tumor tissue of SCLC at our institute (47/47, 100%). The average baseline plasma HGF was 1.28 (range,0.42–4.35) ng/ml. However, plasma HGF was higher in SCLC patients with patients with N3, M1, liver metastasis (LM) and bone metastasis (BM) disease compared with those N0 − 2 (1.25 vs. 1.75 ng/mL, P = 0.000), M0 (1.26 vs. 1.63 ng/mL, P = 0.003), non-LM (1.32 vs. 2.06 ng/mL, P = 0.009), and non-BM (1.35 vs. 1.77 ng/mL, P = 0.047), respectively. Multivariate analysis revealed plasma HGF was an independent predictor for LM and prognostic factor of OS. Conclusion Our results revealed that plasma HGF rather than tumor HGF exhibited a potential role in predicting metastasis and survival in SCLC. Plasma HGF might be used as a non-invasive detecting and monitoring tool for SCLC. | ||
650 | 4 | |a Hepatocyte growth factor | |
650 | 4 | |a Plasma | |
650 | 4 | |a Pan-cancer analysis | |
650 | 4 | |a Small cell lung cancer | |
650 | 4 | |a Metastases | |
653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
700 | 0 | |a Li Tong |e verfasserin |4 aut | |
700 | 0 | |a Bin Liu |e verfasserin |4 aut | |
700 | 0 | |a Fei Qi |e verfasserin |4 aut | |
700 | 0 | |a Zhiyun Zhang |e verfasserin |4 aut | |
700 | 0 | |a Yi Guo |e verfasserin |4 aut | |
700 | 0 | |a Yanxia Liu |e verfasserin |4 aut | |
700 | 0 | |a Ying Wang |e verfasserin |4 aut | |
700 | 0 | |a Lina Zhang |e verfasserin |4 aut | |
700 | 0 | |a Baohua Lu |e verfasserin |4 aut | |
700 | 0 | |a Baolan Li |e verfasserin |4 aut | |
700 | 0 | |a Tongmei Zhang |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t BMC Cancer |d BMC, 2003 |g 23(2023), 1, Seite 10 |w (DE-627)DOAJ000133191 |x 14712407 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g pages:10 |
856 | 4 | 0 | |u https://doi.org/10.1186/s12885-023-10995-z |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/f270c847156348d9b5bf9ed95e9493e3 |z kostenfrei |
856 | 4 | 0 | |u https://doi.org/10.1186/s12885-023-10995-z |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1471-2407 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
951 | |a AR | ||
952 | |d 23 |j 2023 |e 1 |h 10 |